Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia
Status:
Recruiting
Trial end date:
2023-12-10
Target enrollment:
Participant gender:
Summary
To date, antiviral treatment is not recommended for chronic hepatitis B patients with a
normal ALT level and low viremia. The strategy is to closely monitor the patients. However,
evidence suggests that these group are at risk of gradual disease progression and development
of hepatocellular carcinoma. Peginterferon eliminates the hepatitis B virus through immune
regulation and induction of antiviral protein expression. For patients with low viral load,
the clinical cure rate is potentially promising. In this study, we aim to investigate the
efficacy and safety of peginterferon alpha-2b therapy in selected chronic hepatitis B
patients with normal ALT level and low viremia. It is expected to obtain a satisfactory
curative effect. Peginterferon is a marketed drug available in Chinese clinics with
indications of anti-hepatitis B virus.